Eligibility check
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Step 1 of 5
Where are you located?
We confirm your state so we only show studies you can actually reach.
Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.